These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16250642)

  • 1. A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods.
    Kaeppler U; Stiefl N; Schiller M; Vicik R; Breuning A; Schmitz W; Rupprecht D; Schmuck C; Baumann K; Ziebuhr J; Schirmeister T
    J Med Chem; 2005 Nov; 48(22):6832-42. PubMed ID: 16250642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.
    Lu IL; Mahindroo N; Liang PH; Peng YH; Kuo CJ; Tsai KC; Hsieh HP; Chao YS; Wu SY
    J Med Chem; 2006 Aug; 49(17):5154-61. PubMed ID: 16913704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors.
    Chen LR; Wang YC; Lin YW; Chou SY; Chen SF; Liu LT; Wu YT; Kuo CJ; Chen TS; Juang SH
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3058-62. PubMed ID: 15896959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
    Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
    J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays.
    Chen L; Chen S; Gui C; Shen J; Shen X; Jiang H
    J Biomol Screen; 2006 Dec; 11(8):915-21. PubMed ID: 17092912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
    Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
    J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
    Yang Q; Chen L; He X; Gao Z; Shen X; Bai D
    Chem Pharm Bull (Tokyo); 2008 Oct; 56(10):1400-5. PubMed ID: 18827378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
    Lee H; Lei H; Santarsiero BD; Gatuz JL; Cao S; Rice AJ; Patel K; Szypulinski MZ; Ojeda I; Ghosh AK; Johnson ME
    ACS Chem Biol; 2015 Jun; 10(6):1456-65. PubMed ID: 25746232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors.
    Lee CC; Kuo CJ; Hsu MF; Liang PH; Fang JM; Shie JJ; Wang AH
    FEBS Lett; 2007 Nov; 581(28):5454-8. PubMed ID: 17981158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.
    Martina E; Stiefl N; Degel B; Schulz F; Breuning A; Schiller M; Vicik R; Baumann K; Ziebuhr J; Schirmeister T
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5365-9. PubMed ID: 16216498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.
    Ramajayam R; Tan KP; Liu HG; Liang PH
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3569-72. PubMed ID: 20494577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique.
    Chen S; Chen LL; Luo HB; Sun T; Chen J; Ye F; Cai JH; Shen JK; Shen X; Jiang HL
    Acta Pharmacol Sin; 2005 Jan; 26(1):99-106. PubMed ID: 15659121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro.
    Niu C; Yin J; Zhang J; Vederas JC; James MN
    Bioorg Med Chem; 2008 Jan; 16(1):293-302. PubMed ID: 17931870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
    Shao YM; Yang WB; Kuo TH; Tsai KC; Lin CH; Yang AS; Liang PH; Wong CH
    Bioorg Med Chem; 2008 Apr; 16(8):4652-60. PubMed ID: 18329272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits.
    Mukherjee P; Desai P; Ross L; White EL; Avery MA
    Bioorg Med Chem; 2008 Apr; 16(7):4138-49. PubMed ID: 18343121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate specificity and rational design of peptidomimetic inhibitors for SARS coronavirus main protease.
    Wong KB; Wan DC; Chow HF
    Hong Kong Med J; 2014 Aug; 20 Suppl 4():18-21. PubMed ID: 25224113
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitor design for SARS coronavirus main protease based on "distorted key theory".
    Du QS; Sun H; Chou KC
    Med Chem; 2007 Jan; 3(1):1-6. PubMed ID: 17266617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.
    Wang L; Bao BB; Song GQ; Chen C; Zhang XM; Lu W; Wang Z; Cai Y; Li S; Fu S; Song FH; Yang H; Wang JG
    Eur J Med Chem; 2017 Sep; 137():450-461. PubMed ID: 28624700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.